Background illustration for clinical trials search

Paid Clinical Trials Buffalo

Discover 779 paid clinical trials in Buffalo, New York. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.

Filter
2

A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer

for
Pancreatic Ductal Adenocarcinoma (PDAC), G12D Mutated KRAS
Location: Toronto, Ann Arbor MI, Baltimore MD, East Brunswick NJ,
Sponsor: Verastem, Inc.

Sex: All

Age: 18+

Code: NCT07644559

Phase 2, Recruiting

A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)

for
Bladder Cancer
Location: Toronto, Cleveland OH, Morristown NJ, Baltimore MD,
Sponsor: Merck Sharp & Dohme LLC

Sex: All

Age: 18+

Code: NCT07419295

Phase 3, Recruiting

A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer

for
Small Cell Lung Cancer
Location: Toronto, Brampton, Canton OH, Baltimore MD,
Sponsor: Daiichi Sankyo

Sex: All

Age: 18+

Code: NCT06203210

Phase 3, Recruiting

Actinium Therapy for Late-stage Aggressive Sarcomas

for
Advanced Soft Tissue Sarcoma
Location: Toronto, Cleveland OH, New York NY, Rochester MN,
Sponsor: Ratio Therapeutics, Inc.

Sex: All

Age: 18+

Code: NCT07156565

Phase 1, Recruiting

A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)

for
Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma,
Location: Toronto, Pittsburgh PA, New York NY, Lake Success NY,
Sponsor: Bristol-Myers Squibb

Sex: All

Age: 18+

Code: NCT07221149

Phase 2, Phase 3, Recruiting

Interested in new trials?

Get alerts for new trials in your area by subscribing now

Subscriber Image

Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy

for
Urothelial Cancer
Location: Toronto, Mayfield Heights OH, Cleveland OH, Detroit MI,
Sponsor: Bristol-Myers Squibb

Sex: All

Age: 18+

Code: NCT07106762

Phase 2, Phase 3, Recruiting

A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer

for
Ovarian Neoplasms, Fallopian Tube Neoplasms,
Location: Toronto, Mayfield Heights OH, Cleveland OH, Detroit MI,
Sponsor: Eli Lilly and Company

Sex: All

Age: 18+

Code: NCT07213804

Phase 3, Recruiting

A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)

for
Cervical Cancer
Location: Toronto, London, Willow Grove PA, Columbia MD,
Sponsor: Merck Sharp & Dohme LLC

Sex: Female

Age: 18+

Code: NCT07216703

Phase 3, Recruiting

Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)

for
Non-Small Cell Lung Cancer
Location: Toronto, Rochester NY, Cleveland OH, Pittsburgh PA,
Sponsor: Bristol-Myers Squibb

Sex: All

Age: 18+

Code: NCT07100080

Phase 2, Phase 3, Recruiting

A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)

for
Castration-Resistant Prostatic Cancer, Metastasis
Location: Toronto, Pittsburgh PA, Ann Arbor MI,
Sponsor: Merck Sharp & Dohme LLC

Sex: All

Age: 18+

Code: NCT06863272

Phase 1, Phase 2, Recruiting

Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations

for
Non-Small-Cell Lung Cancer,
Location: Toronto, Brampton, Detroit MI, Ottawa, Winchester VA,
Sponsor: ArriVent BioPharma, Inc.

Sex: All

Age: 18+

Code: NCT07185997

Phase 3, Recruiting

M0324 as Monotherapy and in Combination With Pembrolizumab or Chemotherapy in Participants With Selected Advanced Solid Tumors

for
Advanced Solid Tumor
Location: Toronto, New York NY, New Haven CT, San Antonio TX
Sponsor: EMD Serono Research & Development Institute, Inc.

Sex: All

Age: 18+

Code: NCT07166601

Phase 1, Recruiting

TLN-372 in Advanced KRAS Mutant Solid Tumors

for
KRAS Mutant Solid Tumors
Location: Toronto, New York NY, Grand Rapids MI, Boston MA,
Sponsor: Treeline Biosciences, Inc.

Sex: All

Age: 18+

Code: NCT07204340

Phase 1, Recruiting

A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer

for
Endometrial Cancer
Location: Toronto, Syracuse NY, Willow Grove PA,
Sponsor: BioNTech SE

Sex: Female

Age: 18+

Code: NCT06340568

Phase 3, Recruiting

Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)

for
Prostate Cancer Metastatic
Location: Toronto, Cleveland OH, Ottawa, Morristown NJ,
Sponsor: Merck Sharp & Dohme LLC

Sex: All

Age: 18+

Code: NCT06136624

Phase 3, Recruiting

Neoadjuvant Darovasertib in Primary Uveal Melanoma

for
Uveal Melanoma
Location: Toronto, Baltimore MD, New York NY, Grand Rapids MI,
Sponsor: IDEAYA Biosciences

Sex: All

Age: 18+

Code: NCT07015190

Phase 3, Recruiting

A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)

for
Colon Adenocarcinoma, Rectal Adenocarcinoma
Location: Toronto, London, Pittsburgh PA, Morgantown WV,
Sponsor: Merck Sharp & Dohme LLC

Sex: All

Age: 18+

Code: NCT06997497

Phase 3, Recruiting

Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)

for
Non-small Cell Lung Cancer (NSCLC)
Location: Toronto, Fairfax VA, Washington D.C. DC, New York NY,
Sponsor: Nuvation Bio Inc.

Sex: All

Age: 18+

Code: NCT07154706

Phase 3, Recruiting

A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)

for
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Location: Toronto, Pittsburgh PA, Hershey PA, Ottawa,
Sponsor: BeOne Medicines

Sex: All

Age: 18+

Code: NCT06943872

Phase 3, Recruiting

A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015)

for
Malignant Neoplasm
Location: Toronto, Hackensack NJ, New York NY, Columbus OH,
Sponsor: Merck Sharp & Dohme LLC

Sex: All

Age: 18+

Code: NCT06979596

Phase 2, Recruiting